Why Invest in a Cyclotron Machine in India Instead of Relying on External Radioisotope Supply

India''s cancer burden continues to rise, with more than 14 lakh new cancer cases diagnosed every year. As a result, the demand for PET imaging - a medical test used to detect, stage, and monitor cancer - is also increasing, contributing to a global nuclear medicine market valued at over USD 10 billion.

As demand for PET imaging continues to grow, investing in a cyclotron machine in India is becoming increasingly important for hospitals, cancer centres, universities, and research institutions seeking a reliable supply of medical radioisotopes.

Here are five reasons why more institutions are investing in cyclotron technology.

1. Bridge the Gap Between Demand and Cyclotron Capacity

The global nuclear medicine market - which utilizes medical cyclotrons for radioisotope production - is expected to almost double by 2030, reaching USD 21.01 billion, as per a 2026 Yahoo Finance article.

PET scans, or positron emission tomography (PET) scans, are a nuclear medicine imaging technique that relies on radiopharmaceuticals (PET tracers). These tracers are synthesised from radioisotopes produced in a medical cyclotron and must be delivered quickly because they begin to decay soon after production.

From Cyclotron to Patient Care: The Nuclear Medicine Journey

1. Medical Cyclotron
2. Radioisotope Production
3. Radiopharmaceutical Preparation
4. Patient Injection
5. Imaging & Diagnosis

A 2023 study shows that in India, between 2015 and 2023, PET-CT installations increased from 95 to 437 - a 360% growth in PET-CT systems. However, India still has only 25 medical cyclotron facilities, as per the IAEA Cyclotrons Used for Radionuclide Production Database. Based on this data, there are approximately 17-20 PET-CT scanners for every cyclotron facility.

Clearly, demand for PET imaging is growing faster than India''s domestic radioisotope production capacity. PET is used not only in Cancer Care and research, but also to diagnose heart and brain diseases. This is why hospitals in remote and underserved areas often struggle to get a steady supply of PET tracers - they depend on cyclotrons located far away.

One way to bridge this gap is by expanding cyclotron infrastructure beyond the country''s existing production hubs. New medical cyclotron facilities - such as in Bhopal, which can serve central India - can reduce dependence on distant cities like Mumbai and Hyderabad for radioisotope supply.

Whether it''s planning a new cyclotron facility in a metro or a tier-2 city, Global CanCare helps healthcare providers identify the right solution based on their clinical needs, patient volumes, and long-term growth plans.

2. Ensure Reliable Radioisotope Supply with a Medical Cyclotron in India

Every PET scan relies on a radioisotope - a radioactive substance administered to the patient before the scan. It emits signals that help doctors detect cancer, understand how far it has spread, and monitor how well treatment is working. A medical cyclotron is the machine that produces many of these radioisotopes.

The challenge is that these radioisotopes have a very short shelf life. Unlike conventional medicines, they cannot be stockpiled or stored for future use. Fluorine-18 Fluorodeoxyglucose (F-18 FDG), used in most FDG PET scans, has a physical half-life of just 109.8 minutes, meaning it loses half of its radioactivity about every two hours. That also means the supply chain has very little room for delays and needs continuous "just-in-time" delivery.

Radioisotope	Half-life	Common use / application	Cancers / conditions
Fluorine-18 (18F)	109.8 minutes	FDG PET imaging; measures glucose metabolism in the body	Most cancers including lung, breast, colorectal, lymphoma, head & neck, melanoma, esophageal, pancreatic, ovarian, sarcoma
Gallium-68 (68Ga)	67.7 minutes	PET receptor imaging with PSMA, DOTATATE and other tracers	Prostate cancer (PSMA), neuroendocrine tumours (NETs)
Copper-64 (64Cu)	12.7 hours	PET imaging and theranostics research; targeted probes and therapeutic development	Prostate cancer, breast cancer, neuroendocrine tumours, lymphoma (research & theranostics)
Zirconium-89 (89Zr)	78.4 hours	ImmunoPET imaging; labelling antibodies and studying their distribution	Breast cancer (HER2+), lymphoma, solid tumours (immunotherapy planning)
Carbon-11 (11C)	20.4 minutes	PET imaging; brain and metabolic imaging with specific tracers	Brain tumours, prostate cancer (research use)

Note: Production capability depends on cyclotron energy (MeV), target systems and configuration. Some therapeutic isotopes such as Lu-177 and Ac-225 are not typically produced in medical cyclotrons.

According to the OECD Nuclear Energy Agency (OECD NEA), ageing production infrastructure, limited reserve capacity, unexpected shutdowns, and transport disruptions continue to create challenges for radioisotope supply worldwide.

Procuring a medical cyclotron machine in India allows hospitals and research centres to produce these radioisotopes much closer to where patients are treated. This reduces transport time, improves supply reliability, and helps keep PET imaging services running without interruption.

3. Maximise Hospital & Imaging Centre ROI with a High-Efficiency Cyclotron

For hospitals that depend entirely on external suppliers, even a short delay can disrupt operations. This can lead to:

• Decay losses: Since radioisotopes begin decaying immediately after production, delayed shipments may no longer have enough radioactivity for patient use, forcing hospitals to discard them.
• Idle infrastructure: PET-CT systems and specialised staff remain underutilised, while the hospital continues to pay for staff, rent, and equipment maintenance regardless of output.
• Delayed or cancelled scans: Reduced patient throughput, which directly harms clinical outcomes and hospital revenue.

For example, if a PET-CT scanner can perform 25 scans a day but completes only 18 due to isotope supply delays, the hospital still bears the fixed costs of equipment, maintenance, and staff. At an average scan price of Rs 15,000, those seven missed scans represent over Rs 1 lakh in unrealised daily revenue.

The International Atomic Energy Agency (IAEA) recommends producing short-lived radioisotopes close to the hospitals and imaging centres where they are used. Owning an on-site medical cyclotron machine in India addresses these challenges by producing radioisotopes on demand. It reduces decay losses, improves supply reliability, and enables better appointment planning, allowing PET scanners and radiopharmacy teams to operate more efficiently.

Higher equipment utilisation improves the return on investment of PET infrastructure - one of the most capital-intensive investments in modern healthcare. Global CanCare helps healthcare providers achieve this through complete project support, from planning and facility design to AERB approvals, installation, and commissioning.

4. Expand Research, Innovation, and Academic Excellence with an On-Site Cyclotron

Owning an on-site medical cyclotron machine in India transforms a hospital or university into a centre for nuclear medicine research and innovation. Since many research radioisotopes decay within hours, producing them on-site gives scientists and clinicians the flexibility to work with isotopes that would be difficult - or even impossible - to transport over long distances.

This opens the door to developing and testing new PET tracers for diseases such as Alzheimer''s disease, Parkinson''s disease, epilepsy, and cancers of the prostate, breast, and brain.

It also enables first-in-human clinical trials of new radiopharmaceuticals and supports the development of theranostics - where one radiopharmaceutical is used to detect a tumour and a related one is used to treat it.

An on-site cyclotron also makes it easier to collaborate with pharmaceutical companies, biotechnology firms, and research organisations developing the next generation of molecular imaging and targeted radionuclide therapies. For teaching hospitals and medical colleges, it provides hands-on training in radiochemistry, radiopharmacy, medical physics and nuclear medicine, helping build the skilled workforce needed to support India''s rapidly growing nuclear medicine sector.

By bringing research, education, and clinical care together, institutions can accelerate innovation while helping shape the future of precision medicine and theranostics.

5. Secure a Competitive Advantage by Becoming a Radioisotope Hub

A medical cyclotron can do more than support your own PET imaging programme. Depending on its production capacity and regulatory approvals, it can also supply radioisotopes to hospitals, diagnostic centres, and independent imaging facilities that do not have their own cyclotron.

This enables healthcare organisations to build a regional radiopharmaceutical distribution network while creating an additional revenue stream from surplus production capacity. Instead of producing radioisotopes solely for internal use, institutions can supply neighbouring healthcare providers within the isotope''s delivery window, improving access to PET imaging across a wider geographic area.

For example, a healthcare provider in Bhopal, Patna, Coimbatore, or Jaipur could establish a regional radiopharmaceutical distribution network, supplying nearby hospitals and imaging centres that do not have their own cyclotron. This hub-and-spoke model enables institutions to expand their referral network, improve regional access to PET imaging, and generate additional revenue from surplus production capacity.

Global CanCare helps healthcare providers evaluate production capacity, distribution radius, regulatory requirements, and facility design to develop commercially viable cyclotron projects that support both institutional growth and regional healthcare access.

Why Partner with Global CanCare for Your Cyclotron Project?

Setting up a medical cyclotron machine in India is not just an equipment purchase - it''s the creation of a complete nuclear medicine ecosystem. From cyclotron selection and AERB-compliant bunker design to regulatory approvals and radiopharmacy integration, every stage must be carefully planned to ensure safe, efficient, and future-ready operations.

Global CanCare works with hospitals, cancer centres, universities, and research institutions to deliver complete cyclotron solutions - from technology selection to facility design, AERB approvals, equipment supply, installation and commissioning.

Rather than offering a one-size-fits-all solution, we help you select the right cyclotron based on your clinical needs, patient volumes, research objectives, and long-term growth plans. By partnering with leading global cyclotron manufacturers, we deliver world-class technology while helping reduce project costs and maximise long-term value.

From concept to commissioning, Global CanCare is your trusted partner for building or upgrading a future-ready nuclear medicine facility.

Get in touch with our experts to discuss your project

• Email: info@globalcancare.com
• Northern India: +91 81201 15666
• Western India: +91 90987 93898
• Southern & Eastern India: +91 79746 67979
• UK: uk@globalcancare.com
• USA: usa@globalcancare.com
• Australia: australia@globalcancare.com
• UAE: uae@globalcancare.com

Frequently Asked Questions (FAQs)

1. What is a cyclotron in radiology and how does it work?

A cyclotron is a particle accelerator used in radiology to generate short-lived, positron-emitting radioisotopes (like Fluorine-18) for PET scans. It works by using electromagnetic fields to propel charged particles outward in a spiral path, colliding them with target materials to create medical radiopharmaceuticals used to diagnose and treat cancer.

2. How much does a medical cyclotron machine cost in India?

The cost depends on factors such as beam energy, production capacity, target systems, shielding requirements, and facility design. For example:

• Low to medium energy (7-11 MeV): Rs 12-20 crore for equipment only; compact, self-shielded cyclotrons mainly for on-site Fluorine-18 production for PET-CT imaging.
• Standard medical/PET energy (15-19 MeV): Rs 25-45 crore; the industry standard for producing 18F, 11C, 13N, and 15O for regional radiopharmacies.
• High energy (24-30+ MeV): Rs 300-338 crore; large government-scale facilities for producing advanced therapeutic isotopes such as 225Ac, 68Ge, and 123I.

In 2026, the Maharashtra Cabinet approved a Rs 300 crore medical cyclotron facility in Nagpur. Global CanCare helps healthcare organisations identify the right cyclotron solution based on their clinical, operational, and commercial goals.

3. How long does it take to install a cyclotron facility?

A typical cyclotron project can take 12-24 months, depending on site readiness, bunker construction, regulatory approvals, equipment installation, and commissioning. Global CanCare provides end-to-end project delivery, from planning and design to installation, commissioning, and operational readiness.

4. Which medical isotopes can be produced using a cyclotron?

Modern medical cyclotrons can produce several isotopes, including F-18, Ga-68, Cu-64, Zr-89, Iodine-123 (I-123), and Carbon-11 (C-11), depending on the cyclotron''s energy, targets, and production configuration.

5. Do hospitals need a radiopharmacy with a cyclotron?

Yes. A cyclotron is typically integrated with a radiopharmacy to safely process, quality test, and prepare radiopharmaceuticals before they are administered to patients.

6. What regulatory approvals are required to install a cyclotron in India?

Cyclotron facilities must comply with regulations issued by the Atomic Energy Regulatory Board (AERB) and other applicable national authorities. Approval requirements generally cover facility design, radiation safety, commissioning, operation, and quality assurance. Global CanCare can guide you through the AERB approval process, from planning and documentation to commissioning.

7. Who should invest in a cyclotron machine?

Cyclotrons are suitable for cancer hospitals, multi-specialty hospitals, nuclear medicine centres, academic medical institutions, universities, research organisations, commercial radiopharmacies, and government healthcare projects.

8. What is the difference between a medical cyclotron and a research cyclotron?

Medical cyclotrons are primarily designed for routine radioisotope production used in patient care, while research cyclotrons often provide higher flexibility for isotope development, materials research, and experimental applications.

9. Can one cyclotron supply radioisotopes to multiple hospitals?

Yes. Depending on isotope type, production capacity, transportation time, and regulatory requirements, a single cyclotron facility can supply multiple hospitals and imaging centres within its distribution radius.

10. How long do PET radioisotopes remain usable after production?

It depends on the isotope. For example, F-18 has a physical half-life of 109.8 minutes, making production scheduling and transportation critical to maintaining sufficient activity for clinical use.

11. What factors should hospitals evaluate before investing in a cyclotron?

Hospitals should assess patient volumes, PET demand, isotope requirements, available infrastructure, regulatory compliance, radiopharmacy capabilities, distribution opportunities, operational costs, and long-term growth plans.

12. How many cyclotrons are there in the world?

There are over 1,500 cyclotron facilities around the world, and the IAEA has recently updated its interactive map and database featuring 1,300 of these cyclotron facilities from 95 countries.

References

1. Yahoo Finance. Nuclear Medicine Market by Type, Application, and Region. Accessed July 2026.
2. National Center for Biotechnology Information (NCBI). Current Status and Future Directions of Cyclotron Production of Medical Radioisotopes. Accessed July 2026.
3. International Atomic Energy Agency (IAEA). Cyclotrons. Accelerator Knowledge Portal. Accessed July 2026.
4. International Atomic Energy Agency (IAEA). Cyclotrons Used for Radionuclide Production Database. Accessed July 2026.
5. Atomic Energy Regulatory Board (AERB). List of PET-CT Centres Licensed by AERB. As on May 20, 2026.
6. National Center for Biotechnology Information (NCBI). Positron Emission Tomography Radiopharmaceuticals. Accessed July 2026.
7. OECD Nuclear Energy Agency (OECD-NEA). The Supply of Medical Radioisotopes. Accessed July 2026.
8. International Atomic Energy Agency (IAEA). Medical Radioisotopes: Production and Applications. IAEA Bulletin. Accessed July 2026.
9. The Indian Express. Nagpur to Get High-Energy Medical Cyclotron Project under MahaCare Cancer Initiative. Accessed July 2026.
10. International Atomic Energy Agency (IAEA). Cyclotrons: What Are They and Where Can You Find Them? Accessed July 2026.